Ravicti FDA Approval History
FDA Approved: Yes (First approved February 1, 2013)
Brand name: Ravicti
Generic name: glycerol phenylbutyrate
Dosage form: Oral Liquid
Company: Hyperion Therapeutics
Treatment for: Urea Cycle Disorders
Ravicti (glycerol phenylbutyrate) is a nitrogen-binding agent for the chronic management of patients with urea cycle disorders.
Development Timeline for Ravicti
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.